/
Other
CLL/SLL
9
Pipeline Programs↗
7
Active Trials↗
10
Companies Involved↗
CLL/SLL is an early-stage landscape with 9 programs across 10 companies. The most active players are Dizal Pharmaceuticals, Fochon Pharmaceuticals, Ltd.. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 34
Approved
No programs
Analysis
Trial Status
16
clinical trials
Recruiting5 · 31%
Completed4 · 25%
Terminated3 · 19%
Active, not recruiting2 · 13%
Withdrawn1 · 6%
Unknown status1 · 6%
Clinical Trials
Trial Activity
16 trials
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
Recruiting·—·Phase 2·NCT07014917·62 enrolled
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Completed·—·Phase 2·NCT02135133·27 enrolled
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
Terminated·—·Phase 1·NCT00543114·9 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)